Myeloma Cancer Trials
54767414SMM3001
54767414SMM3001 – A phase III randomized, multicenter study of subcutaneous daratumumab versus active monitoring in subjects with high-risk smoldering multiple myeloma.
-
What type of cancer? What stage?
- Smoldering multiple myeloma.
-
Who is eligible?
- Diagnosed within 5 years.
-
How will I be treated?
- Daratumumab – an antibody-based drug, directed against CD38.
For physicians: more information about this specific trial at clinicaltrials.gov.
-
When you own a house, you take care of it with regular maintenance. When you own a car, you take it to ...
Continue Reading -
Let’s start with some good news: colorectal cancer diagnoses and mortality rates are on the decline. ...
Continue Reading
/
View All